Cure8 research brief
Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement existing monitoring for flares and treatment response.
Clinicians and researchers studying IBD biomarkers, and patients with IBD who are on or considering biologic therapy and are interested in monitoring strategies.
The study measured blood platelet indices and platelet aggregation in adult IBD patients and compared values by clinical disease activity. Patients with active disease had higher PLR and NLR and lower MPV; platelet aggregation was also higher.
The abstract states these parameters changed with biological treatment, suggesting a possible role for tracking response to biologic therapy. This is an abstract-level report (posted to a preprint server).
The findings are preliminary: the design is cross-sectional and the authors recommend longitudinal validation before these markers are used routinely in clinical practice. If you are a patient on biologic therapy, discuss any interest in platelet-index monitoring with your care team rather than making changes based on this single study.
The report focuses on laboratory markers rather than symptoms or treatment changes; it does not provide treatment recommendations or validated cutoffs ready for clinical use.
This is an abstract posted on ResearchSquare (preprint-style posting) reporting a cross-sectional study. The authors themselves call for longitudinal validation and standardized reference ranges. Findings from an abstract should be interpreted cautiously until peer-reviewed and replicated.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
